Ferring Pharmaceuticals Showcases Innovations in Fertility Care
Ferring Pharmaceuticals is gearing up for an impactful presentation at the upcoming annual conference of the American Society for Reproductive Medicine (ASRM). This year’s event is set to take place over several days, offering a platform for healthcare experts and professionals to delve into the latest advances in reproductive medicine.
Ferring's Contribution to Fertility Medicine
At this year's ASRM Congress, Ferring will unveil findings from four crucial abstracts, each designed to enhance the knowledge of healthcare practitioners and fertility clinic teams. Sharing important insights into various aspects of reproductive health, Ferring's presentations promise to broaden the understanding of fertility care and its challenges.
According to Sasmira Lalwani, Senior Medical Director of Reproductive Medicine at Ferring Pharmaceuticals, the aim is to educate and empower health professionals. "We are excited to disseminate our research findings at the ASRM Congress, which reflects our commitment to advancing reproductive health. The diversity in family-building needs drives our approach, ensuring we cater to unique patient circumstances rather than applying a one-size-fits-all solution to fertility care,” she stated.
Overview of the Research Presentations
The abstracts presented by Ferring will tackle an array of vital topics within reproductive medicine, showcasing the company's dedication to addressing pressing issues faced by individuals and practitioners alike.
1. **Advancing Fertility Equity**: Focused on upliftment and support for Black women through culturally responsive solutions, this presentation seeks to bridge gaps in fertility care. It is set for Poster #24 and is scheduled for release after an embargo lifting on October 21.
2. **Utilization Patterns**: This study explores the engagement of advanced practice providers in reproductive endocrinology through a national survey conducted in 2023. The findings will be shared in Oral Presentation #184, with an embargo until October 22.
3. **Ovarian Hyperstimulation Syndrome**: An analysis concerning the risk factors related to gonadotropin selection during ovarian stimulation for high responders will also be presented. The Oral Presentation #154 will be accessible after the embargo on the same date.
4. **eLearning Impact**: This initiative assesses the efficacy of an eLearning platform aimed at improving education among fertility professionals. This engaging topic will be showcased in Poster #652 and will be available following its release on October 23.
Commitment to Community and Advocacy
Ferring’s commitment goes beyond just data presentations. They will also lead a significant discussion titled “Addressing Gaps and Reaching More Patients: Impacting Family Building Through Advocacy and Legislation,” scheduled for October 21. This panel discussion will examine both state and federal policies that significantly affect access to fertility services and treatment for those experiencing challenges in building their families.
Tim Clark, the Director of Government Affairs at Ferring, will moderate this important conversation. Among the esteemed panelists are:
- Serena H. Chen, MD – Renowned Reproductive Endocrinologist and Director of Advocacy at CCRM NJ.
- Michael A. Thomas, MD – A prominent figure in Obstetrics and Gynecology and past president of ASRM.
- Sean B. Tipton, MA – Chief Advocacy & Policy Officer at the American Society for Reproductive Medicine.
Understanding Ferring Pharmaceuticals
Ferring Pharmaceuticals has established itself as a leader in reproductive medicine over its 50-plus years in operation. Fueled by their vision to assist individuals in becoming parents, the company is deeply invested in evolving reproductive healthcare.
Headquartered in Saint-Prex, Switzerland, Ferring operates with a workforce exceeding 7,000 across more than 100 countries. The U.S. branch, located in Parsippany, New Jersey, employs over 900 dedicated individuals, continually striving to enhance patient outcomes through innovative treatments and supportive educational resources.
Ferring Pharmaceuticals remains a beacon of hope for individuals navigating the complexities of fertility and family building, reinforcing their identity as a compassionate advocate for patient needs within the medical community.
Frequently Asked Questions
What is the ASRM Congress?
The ASRM Congress is an annual event that brings together professionals in reproductive medicine to share research, advancements, and best practices in the field.
What presentations will Ferring Pharmaceuticals conduct?
Ferring will share findings on topics such as fertility equity, utilization of advanced practice providers, risk of ovarian hyperstimulation syndrome, and the impact of eLearning for fertility professionals.
Who are the panelists in Ferring's discussion?
Panelists include Dr. Serena H. Chen, Dr. Michael A. Thomas, and Sean B. Tipton, with a focus on advocacy and legislation affecting fertility treatments.
How long has Ferring Pharmaceuticals been in operation?
Ferring Pharmaceuticals has been operating for over 50 years since its inception in 1950, aiming to enhance reproductive health services.
What is Ferring’s commitment to reproductive medicine?
Ferring is dedicated to advancing fertility options and care, supporting diverse needs, and providing healthcare professionals with educational resources.
